Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib

Phase 2TerminatedNCT01783522

Beth Faiman9 enrolled

Overview

This randomized phase II trial studies glutamine in preventing peripheral neuropathy in patients with multiple myeloma who are receiving bortezomib. Glutamine may help prevent peripheral neuropathy in patients receiving chemotherapy

PRIMARY OBJECTIVES: I. Estimate the objective effect size of glutamine compared to placebo as a prophylactic intervention to prevent bortezomib-induced peripheral neuropathy in multiple myeloma patients 4 months after their first dose of study drug. SECONDARY OBJECTIVES: I. Estimate whether glutamine delays or prevents the onset or worsening of any neuropathy as determined by National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) v4.03 criteria. II. Determine if glutamine may improve adherence to bortezomib therapy. III. Assess response rate (RR) and clinical benefit response rate (CBR) according to uniform international response criteria and modified European Group for Blood and Marrow Transplantation (EBMT) criteria. IV. Determine if glutamine may improve quality of life (QOL) at 4 months. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive glutamine orally (PO) twice daily (BID). Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive placebo PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Chemotherapeutic Agent Toxicity Multiple Myeloma Peripheral Neuropathy

Interventions

glutamineDRUG

Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.

quality-of-life assessmentOTHER

Ancillary studies

placeboOTHER

Given PO

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with a diagnosis of multiple myeloma who received bortezomib at a dose of 1.3mg/m2 SQ weekly * No evidence of severe pre-existing peripheral neuropathy, NCI-CTCAE v4.03 =\< 2 * Performance status =\< 2 on the Eastern Cooperative Oncology Group (ECOG) performance scale Exclusion Criteria: * Concurrent use of thalidomide, vincristine, platinum compound, or other agent known to cause significant neuropathy (concurrent lenalidomide will be allowed) * Hospitalization with clinical evidence of active infections as manifested by recurrent fevers, positive blood culture results, or requiring intravenous antibiotic therapy * Inadequate liver and renal function with liver transaminases 3x the upper limit of normal * Glomerular filtration rate (GFR) according to Cockcroft-Gault \< 30 mL/min * Uncontrolled congestive heart failure * Uncontrolled mood disorders * Fasting blood glucose \>150mg/dL or blood sugar (non-fasting) \>200mg/dL if no history of diabetes. Uncontrolled diabetes with HgA1C greater 7% with last evaluation. * Seizure disorder * Monosodium glutamate (MSG) allergy or soy allergy * Life expectancy of shorter than 3 months based on clinical laboratory parameters and the investigator's opinion * Uncorrected Vitamin B12 or folate deficiency on last evaluation. * Use of over the counter (OTC) supplements other than one multivitamin tablet a day * Women who are pregnant or breastfeeding

Locations (1)

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Cleveland, Ohio, United States

Outcomes

Primary Outcomes

Degree of Peripheral Neuropathy (PNP)

The Neuropathy Impairment Score -Lower Limbs (NIS-LL) is the objective measurement of PNP symptoms. The degree of PNP will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03. The CTCAE is a 0-5 scale that assesses severity of neuropathy related to cancer therapy with higher scores meaning more symptoms A difference of 2 points between groups is considered significant. This measure will be performed at baseline and at 4 months.

Time frame: up to 4 months from start of study

Secondary Outcomes

Adherence to Bortezomib Treatment

Adherence reported as a percentage based on number of doses of study drug taken divided by the expected number of doses of study drug expected to be taken for the study duration.

Time frame: Up to 4 months

RR (Complete Remission [sCR+CR+Very Good Partial Remission [VGPR]+Partial Remission [PR])

RR (sCR+CR+VGPR+PR) according to uniform international response criteria and CBR (RR+MR according to modified EBMT criteria) will be assessed with SPEP, 24h UPEP, serum urine immunofixation, and serum free light chain assay at the start of each cycle and after completion of the 4th cycle.

Time frame: up to 4 months from start of study

Average Change in Quality of Life Scores From Baseline to End of Study

Quality of life will be measured on the 27-item Functional Assessment of Cancer Therapy-General (FACT-G) including 26 summed items (responses 0 to 4 to equal a possible total score 0-108). Higher scores represent better quality of life. Average change in Quality of Life scores from baseline to end of study will be reported for each separate arm

Time frame: from baseline to end of study at 4 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.